NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Belite Bio, Inc (BLTE) Stock Analysis

Belite Bio, Inc (BLTE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BLTE

$193.61

+$22.52 (+13.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLTE with… →

BLTE Key Statistics

As of Sep 4, 2026
Trading
Open
$172.77
Previous Close
$171.09
Day's Range
172.77–193.88
52-Week Range
64.80–200.00
Volume
738.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.24
Valuation
Market Cap
$7.80B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
100.64
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.10
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$77.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
40.27M
1-Year Return
+197.22%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
188.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BLTE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+21.04%
2025+153.50%
2024+37.92%
2023+51.77%
2022 (partial year)+184.66%

As of September 4, 2026.

BLTE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$77.61M—
2024$0.00−$36.14M—
2023$0.00−$31.63M—
2022$0.00−$12.65M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.21M−$77.61M—
2024$0.00—−$40.00M−$36.14M—
2023$0.00—−$31.67M−$31.63M—
2022$0.00—−$12.82M−$12.65M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BLTE Valuation vs Biotechnology Median

Median of 656 stocks
MetricBLTEBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Belite Bio, Inc (BLTE) carries a market capitalisation of $7.80B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 41.

The 52-week range on file runs from $64.80 to $200.00. The most recent close on file for BLTE is $193.61, dated September 4, 2026. That is +$22.52 (+13.16%) against the previous close. The latest close sits 198.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $77.61M. The reported profit margin is 0%. Trailing earnings per share are −3.1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 100.64.

The reported beta is −1.24. Annualized volatility over the trailing 4 years is 60.19%. Over the trailing twelve months the price has returned +197.22%. Across 3 years the annualized return works out at +80.36%.

Growth & Income

The record shows no dividend for BLTE.

2026 is still running; the price is +21.04% year to date. The strongest complete calendar year on file is 2025 at +153.50%; the weakest is 2024 at +37.92%. Of the 3 complete calendar years on file, 3 finished higher.

Peer Comparison

Belite Bio, Inc (BLTE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Belite Bio, Inc BLTE $7.80B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Belite Bio, Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Visit website →